Double Blind Placebo Controlled Dose Ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single Ascending Subcutaneous and Oral Doses of GLPG0187 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 19 Jan 2010
At a glance
- Drugs GLPG 0187; GLPG 0187
- Indications Breast cancer; Cancer metastases; Prostate cancer
- Focus Adverse reactions; Biomarker
- Sponsors Galapagos NV
- 19 Jan 2010 Status changed from active, no longer recruiting to completed as reported in a Galapagos NV media release.
- 19 Jan 2010 Favourable tolerability results have been reported in a Galapagos NV media release.
- 03 Oct 2009 Planned end date changed from 1 Oct 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.